Recent studies have found that blocking cytokine pathways, such as the IL‐1β/IL‐6 pathway to control residual inflammation risk, can significantly reduce cardiovascular events for CAD patients under active use of lipid-lowering drugs41. Here, IL6 is linked to coronary artery disorder.